PubMed Journals Articles About "VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q" RSS

11:37 EDT 18th September 2018 | BioPortfolio

VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q articles that have been published worldwide.

More Information about "VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q" on BioPortfolio

We have published hundreds of VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q news stories on BioPortfolio along with dozens of VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q Clinical Trials and PubMed Articles about VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q Companies in our database. You can also find out about relevant VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q Drugs and Medications on this site too.

Showing "VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate VAX2012Q" PubMed Articles 1–25 of 7,500+

Quadrivalent influenza vaccine: What is changed and what are the benefits?

Currently, circulating viruses responsible for annual seasonal influenza epidemics belong to two influenza A subtypes, A(H1N1) and A(H3N2), and to two antigenically distinct type B lineages, B/Yamagata and B/Victoria lineages. Like diseases due to influenza A virus, influenza B virus diseases may have severe consequences and should be prevented. Until now, in France, the vaccines used to prevent seasonal influenza were trivalent, systematically targeting viruses belonging to both A subtypes and to one or ot...

Cell culture-derived flu vaccine: Present and future.

The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV) formulations for seasonal vaccination by including both influenza B lineages. Three parallel approaches for producing influenza vaccines are attracting the interest of many vaccine manufacturing companies. The first and oldest is the conventional egg-derived in...

Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.

The European Medicines Agency (EMA) requires vaccine manufacturers to conduct enhanced safety surveillance (ESS) of seasonal influenza vaccines including a near real-time evaluation of collected data. The objective was to identify whether the use of passive surveillance or active surveillance provides different results of reported adverse events of interest (AEIs) by specified age strata and AEI type. We report the weekly incidence rates of AEIs within 7 days following seasonal influenza vaccination using ...

The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: results of two phase 3 studies.

Quadrivalent live attenuated influenza vaccine (Q/LAIV) has not been assessed in Japanese children.

Development and Regulation of Novel Influenza Virus Vaccines: A United States Young Scientist Perspective.

Vaccination against influenza is the most effective approach for reducing influenza morbidity and mortality. However, influenza vaccines are unique among all licensed vaccines as they are updated and administered annually to antigenically match the vaccine strains and currently circulating influenza strains. Vaccine efficacy of each selected influenza virus vaccine varies depending on the antigenic match between circulating strains and vaccine strains, as well as the age and health status of the vaccine rec...

Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications on Seasonal Vaccine Strain Selection and Vaccine Performance.

Reduced seasonal influenza vaccine effectiveness (VE) was observed in individuals who received repeated annual vaccinations. Pre-existing influenza antibody levels were also found inversely correlated with post-vaccination titers. These reports suggest that pre-existing immunity may affect contemporary seasonal vaccine performance.

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy.

No reports have described the immunogenicity and boosting effect of the quadrivalent inactivated influenza vaccine (QIV) in adults with inflammatory bowel disease.

Seasonal influenza vaccine effectiveness at primary care level, Hong Kong SAR, 2017/2018 winter.

The 2017/18 winter influenza season in Hong Kong SAR started in early January 2018, predominated by influenza B/Yamagata. We collaborated with private medical practitioners of our sentinel surveillance system to collect respiratory specimens and clinical information from patients with influenza-like illness for estimation of the influenza vaccine effectiveness (VE) using the test-negative case-control design. We found that the overall VE was 59.1% (95%CI 41.1 to 71.8%) against all influenza and 53.5% (95%CI...

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.

Intranasally administered live attenuated influenza vaccine (LAIV) was initially licensed in the United States in 2003 as a trivalent formulation (LAIV3) (FluMist, MedImmune, LLC). Quadrivalent live attenuated influenza vaccine (LAIV4) (FluMist Quadrivalent, MedImmune) has been licensed in the United States since 2012 and was first available during the 2013-14 influenza season, replacing LAIV3. During the 2016-17 and 2017-18 influenza seasons, the Advisory Committee on Immunization Practices (ACIP) recommen...

Immune History and Influenza Vaccine Effectiveness.

The imperfect effectiveness of seasonal influenza vaccines is often blamed on antigenic mismatch, but even when the match appears good, effectiveness can be surprisingly low. Seasonal influenza vaccines also stand out for their variable effectiveness by age group from year to year and by recent vaccination status. These patterns suggest a role for immune history in influenza vaccine effectiveness, but inference is complicated by uncertainty about the contributions of bias to the estimates themselves. In thi...

Improving influenza vaccines: challenges to effective implementation.

Influenza virus causes contagious respiratory illness and remains a major burden on healthcare systems and the economy. Seasonal influenza vaccine is the most cost-effective way to combat the disease. However, underestimation of disease severity and controversy over vaccine safety and effectiveness hampers public confidence in vaccination. Action is needed to restore public confidence and improve vaccine uptake. Tailoring seasonal influenza vaccines according to immune responsiveness and infection/vaccinati...

Determinants of healthcare workers' willingness to recommend the seasonal influenza vaccine to diabetic patients: a cross-sectional survey in Ningbo, China.

Seasonal influenza vaccine uptake among diabetic patients is low in China. Recent studies showed healthcare workers'(HCWs') recommendation is an effective way to promote influenza vaccination. This study aimed to assess HCWs' willingness to recommend influenza vaccine to diabetic patients and identify the predictors of this willingness.

Efforts to Improve the Seasonal Influenza Vaccine.

Influenza viruses infect approximately 20% of the global population annually, resulting in hundreds of thousands of deaths. While there are Food and Drug Administration (FDA) approved antiviral drugs for combating the disease, vaccination remains the best strategy for preventing infection. Due to the rapid mutation rate of influenza viruses, vaccine formulations need to be updated every year to provide adequate protection. In recent years, a great amount of effort has been focused on the development of a un...

Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.

Since the mid-1980s, two lineages of influenza B viruses have been distinguished. These can co-circulate, limiting the protection provided by inactivated trivalent influenza vaccines (TIVs). This has prompted efforts to formulate quadrivalent influenza vaccines (QIVs), to enhance protection against circulating influenza B viruses. This review describes the results obtained from seven phase III clinical trials evaluating the immunogenicity, safety, and lot-to-lot consistency of a new quadrivalent split-virio...

Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16.

Based on previous observations during pandemics and seasonal epidemics, pregnant women are considered at risk of developing severe influenza outcomes after influenza infection. With the aim of preventing severe influenza illness, the World Health Organization (WHO) includes pregnant women as a target group for seasonal influenza vaccination. However, influenza vaccine uptake during pregnancy remains low in many countries, including Spain. The objectives of this study were to increase the evidence of pregnan...

Seasonal influenza immunisation: Strategies for older adults.

Adults over the age of 60-65 years suffer disproportionally from seasonal influenza, experiencing high rates of complications, exacerbation of underlying medical comorbidities, and excess mortality. Thus, older adults are an important priority for influenza immunisation campaigns. Unfortunately, older adults generally display lower immune responses to standard influenza vaccines because of immunosenescence, with resulting suboptimal vaccine effectiveness. Thus, the development of improved vaccines that hei...

Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Despite the widespread use of seasonal influenza vaccines, there is urgent need for a universal influenza vaccine to provide broad, long-term protection. A number of factors underpin this urgency, including threats posed by zoonotic and pandemic influenza A viruses, suboptimal effectiveness of seasonal influenza vaccines, and concerns surrounding the effects of annual vaccination. In this article, we discuss approaches that are being investigated to increase influenza vaccine breadth, which are near-term, r...

Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.

The frequency with which the 2 B lineages have been found to cocirculate in a season has been on the rise, which has spurred the need for a quadrivalent influenza vaccine (QIV) to protect against both B lineages. The World Health Organization (WHO) recommended that QIV include both B lineages beginning in the 2013-2014 flu season. This study was conducted to evaluate the immunogenicity and safety of an egg-cultivated QIV in healthy Korean children and adolescents aged ≥ 6 months to < 19 years.

Predicting Influenza H3N2 Vaccine Efficacy from Evolution of the Dominant Epitope.

We predict vaccine efficacy with a measure of antigenic distance between influenza A(H3N2) and candidate vaccine viruses based on amino acid substitutions in the dominant epitopes. In 2016-2017, our model predicts 19% efficacy compared to 20% observed. This tool assists candidate vaccine selection by predicting human protection against circulating strains.

Vaccination: What's new?

Vaccination practices in Germany are driven by scientific developments and a complex regulatory environment. Some important developments in 2018 are described here: Starting in 2018 only quadrivalent influenza vaccines will be used for the seasonal vaccination. Despite the availability of meningococcus ACWY and B vaccines and their use in other countries only the type C conjugate vaccine will be used for the routine vaccination of children. For the first time there is now an official recommendation to also ...

Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study.

The World Health Organization (WHO) recommends that countries prioritize pregnant women for influenza vaccination, yet few low- or middle-income countries (LMICs) have implemented maternal influenza immunization programs. To inform vaccine decision-making and operational planning in LMICs, there is a need to document and share experiences from countries that provide seasonal influenza vaccine to pregnant women, particularly those with high coverage, like El Salvador.

Will a Quadrivalent Vaccine Solve the Problem of Influenza B Mismatches?

Mouse strain and sex as determinants of immune response to trivalent influenza vaccine.

The study examined the influence of sex and mouse strain on germinal center (GC) reaction and antibody responses to seasonal split trivalent influenza vaccine (TIV).

Beliefs, attitudes, and barriers associated with the uptake of the seasonal influenza vaccine among patients visiting primary healthcare clinics.

To explore beliefs, attitudes, and barriers associated with uptake of the seasonal influenza vaccine among visitors to primary healthcare clinics.

Forecasting demand for maternal influenza immunization in low- and lower-middle-income countries.

Immunization of pregnant women against seasonal influenza remains limited in low- and lower-middle-income countries despite being recommended by the World Health Organization (WHO). The WHO/PATH Maternal Influenza Immunization Project was created to identify and address obstacles to delivering influenza vaccines to pregnant women in low resource setting. To gain a better understanding of potential demand from this target group, we developed a model simulating pregnant women populations eligible for vaccinat...

Quick Search